Annales des Mines – Industrial realities – Number 2023/4 – November 2023 – Biotherapies and bioproductions

2023-11-08 23:00:00
Page 5: Sylvie Retailleau – Preface | Page 6: Bernard Celli and Jean-Marc Grognet – Introduction | Page 7 to 9: Michel Rao and Élodie Pliquet – Making France a leading country in biotherapies and bioproduction | Page 10 to 14: Emmanuel Dequier – The Great Biomedicine Challenge | Page 15 to 17: Lise Alter – The role of the Health Innovation Agency (AIS) | Page 18 to 22: Laurent Lafferrère – France Biolead, the bioproduction of biomedicines | Page 23 to 26: Thierry Hulot – Biotherapies: adapting to the specificities of innovative therapy drugs | Page 27 to 32: Chloé Evans, Clara Magi and Franck Mouthon – Biotechnologies, industry of the present and the future | Page 33 to 36: Franck Letimonnier and Didier Samuel – A fundamental and clinical research issue | Page 37 to 40: Patrick Chaton, Bernard Maillere and François Jacq – Technological research, a challenge for biotherapies and their bioproduction | Page 41 to 46: Philippe Lamoureux – Industrial bioproduction in France. How Leem contributes to the structuring and success of the bioproduction sector in France | Page 47 to 50: Élodie Thierion, Jessica Leygues and Christian Deleuze – The action of competitiveness clusters | Page 51 to 55: Cécile Martinat, Anne Jouvenceau and Christophe Junot – What role for research and academic innovation in the field of biotherapies and their bioproduction? Presentation of the Priority Research Program and Equipment (PEPR). Biotherapies and bioproduction of innovative therapies | Page 56 to 59: Laura Piovesan, Cristina Niculescu and Valeria Iansante – Challenges and Opportunities in Biotherapies and Bioproduction – an EIB Investment Perspective | Page 60 to 63: Pascale Augé – Innovation and technology transfer from public research: Inserm Transfert, a strategy focused on international competitiveness and long-term vision | Page 64 to 67: Jacques Volckmann – Sanofi meets the challenges of bioproduction | Page 68 to 71: Stéphane Bancel – Moderna’s messenger RNA: a therapeutic revolution | Page 72 to 81: Herbert J. Guedegbe, Ludovic Burlot and Patrick Delavault – Biomedicines derived from plasma and therapeutic proteins: issues and perspectives | Page 82 to 86: Erica Telford, Fabrice Porcheray, Sandrine Halfen, Armelle Pasquet, Nicolas Pulik, Marion Fanjat, Hervé Raoul and Yazdan Yazdanpanah – Strategies in the fight against infectious diseases: the role of the ANRS | Emerging infectious diseases | Page 87 to 91: Éric Quéméneur – Viral vectors in cancer immunotherapy | Page 92 to 94: Jérôme Larghero, Stéphanie Decoopman and Philippe Menasché – Bioproduction in cell therapies: the case of CAR-T cells by the MEARY platform | Page 95 to 99: Alain Lamproye – The industrialization of gene therapies: the example of Yposkesi | Page 100 to 104: Fabienne Bartoli, Joachim Baba and Salah Ghabri – The challenges of the therapeutic evaluation of biotherapies: focus on innovative therapy drugs | Page 105 to 108: Philippe Bouyoux and Jean-Patrick Sales – The challenges of pricing biotherapies | Page 109 to 111: Alain Fischer – Biotherapies: opportunities and accessibility | Page 112 to 116: Pierre-Henri Duée, Sophie Crozier, Florence Jusot and Jean-François Delfraissy – The ethical issues raised by biotherapies.
1700619437
#Annales #des #Mines #Industrial #realities #Number #November #Biotherapies #bioproductions